Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis

Meta-analysis (n=1,065) found improvement in progression free survival in the adjuvant vs neoadjuvant group (15-year PFS, 29% v 36%; HR, 1.25; 95% CI, 1.07 to 1.47]; P = 0.01) with no differences in late grade ≥ 3 gastrointestinal or genitourinary toxicity.

Source:

Journal of Clinical Oncology